's Chart of the Day - Recro Pharma
Related Stocks
 REPH - Recro Pharma Inc

The Barchart Chart of the Day belongs to the pharmaceutical company Recro Pharma (REPH). I found the stock by sorting Barchart's Top 100 Stocks list first by the most frequent number of new highs in the last month, Then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy on 10/21 the stock gained 28.55%.'

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (DEX) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania.


Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the website when you read this report.

Barchart technical indicators:

  • 100% technical buy signals
  • 194.30+ Weighted Alpha
  • 144.21% gain in the last year
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 15 new highs and up 54.71% in the last month
  • Relative Strength Index 75.07%
  • Technical support level at 17.16
  • Recently traded at 16.85 with a 50 day moving average of 12.74

Fundamental factors:

  • Market Cap $392 million
  • Revenue expected to grow 31.00% this year and another 15.10% next year
  • Earnings estimated to increase 85.90% this year and an additional 143.60% next year
  • Wall Street analysts issued 4 strong buy recommendations on the stock
  • The individual investors following the stock on Motley Fool are split voting 9 to 9 that the stock will beat the market
  • 3,215 investors are monitoring the stock on Seeking Alpha